Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into ...

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today ...

New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancers GVHD trial launching through non-dilutive ...

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) ...

MiNK Therapeutics, Inc., a biopharmaceutical company focused on allogeneic invariant natural killer T (iNKT) cell therapies, announced the publication of a peer-reviewed article in Frontiers in ...

This past Friday, July 12th, 2025, MiNK Therapeutics (INKT) closed the day higher by 730% to $64.17 per share. The reason for this massive surge in stock price was because of the release of data from ...

BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell BrightPath Bio (Tokyo Stock Exchange Growth ...

MiNK Therapeutics (NASDAQ: INKT) saw its stock price soar by over 530% today—hitting a peak of $65.55—after the company revealed a potential breakthrough in cancer treatment. MiNK announced that one ...